Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit model
- 24 July 2009
- Vol. 27 (40) , 5496-5504
- https://doi.org/10.1016/j.vaccine.2009.06.105
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protectionJournal of Clinical Investigation, 2008
- Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit modelAntiviral Research, 2008
- Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of DryvaxJournal of Virology, 2008
- Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus AnkaraJournal of General Virology, 2007
- Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challengeVaccine, 2007
- Rabbitpox Virus and Vaccinia Virus Infection of Rabbits as a Model for Human SmallpoxJournal of Virology, 2007
- Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccineVaccine, 2005
- Smallpox and pan -Orthopox Virus Detection by Real-Time 3′-Minor Groove Binder TaqMan Assays on the Roche LightCycler and the Cepheid Smart Cycler PlatformsJournal of Clinical Microbiology, 2004
- Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulenceJournal of General Virology, 1991
- MVA-Stufenimpfung gegen PockenDeutsche Medizinische Wochenschrift (1946), 1974